Skip to main content

Day: May 2, 2024

No. 8 2024 Q1 EBITDA on par with expectations

Q1 revenue and EBITDA are in line with our expectations. We confirm our 2024 EBITDA guidance of DKK 600m. CEO Jens Andersen says:“As expected, all segments showed negative growth in Q1 2024, with March performing slightly better than January and February. In April, Solar Danmark’s growth almost edged into positive territory. As a result of Solar Danmark winning more projects compared to the same period last year, we remain confident this positive development will continue for the rest of 2024. Consequently, we confirm our 2024 EBITDA guidance of DKK 600m.” Q1 key financial messagesQ1 EBITDA is on par with expectations. Net working capital at the end of the quarter continued to fall. 2024 EBITDA guidance of DKK 600m confirmed.Adjusted organic growth reflects an adjustment for the early timing of Easter when compared to Q1 2023....

Continue reading

ForFarmers trading update Q1 2024: Like-for-like volume growth and strong increase operational profitability

Lochem, 2 May 2024 ForFarmers trading update Q1 2024Like-for-like volume growth and strong increase operational profitability Pieter Wolleswinkel, CEO ForFarmers: “Our (compound) feed volumes show an increase. This is a great achievement and shows that we have been able to further strengthen our market position with our focused local market approach. The volume development confirms that we are contributing to a good return on the farm/a profitable farming business. Our effective buying and selling strategy where we operate close to the market, combined with our actions to reduce our cost base, significantly improved operating profitability in the first quarter. The integration of Piast’s operations in Poland is progressing well. The reorganisation in the United Kingdom is also on schedule. These developments show that we are on...

Continue reading

Interim Report Q1 2024: GN Store Nord delivered organic revenue growth of 5% reaching an EBITA margin of 12.5%

HighlightsGN delivered continued execution across the three divisions resulting in 5% organic revenue growth for the Group The Hearing division delivered continued market share gains leading to 14% organic revenue growth, resulting in 8.2 percentage point increase in the divisional profit margin supported by synergies and a successful ReSound Nexia roll-out The Enterprise division continued its relentless commercial execution in a stabilizing market leading to 0% organic revenue growth. The divisional profit margin increased by 5.7 percentage points driven by easing freight costs, synergies, product mix, and strict cost control The Gaming & Consumer division delivered organic revenue growth of 0% due to a demanding comparison base from Q1 2023. The divisional profit margin increased by 3.8 percentage points driven by easing freight...

Continue reading

Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: results of Simplified Squeeze-Out Acceptance Period of TPG on Intervest

Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the results of Simplified Squeeze-Out Acceptance Period of TPG on Intervest. Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de resultaten aan van de Aanvaardingsperiode van het vereenvoudigd uitkoopbod van TPG op Intervest. Chère Madame, Cher Monsieur, Veuillez trouver ci-dessous les liens vers le récent communiqué de presse d’Intervest Offices & Warehouses concernant les résultats de la période d’acceptation de l’offre de reprise simplifiée de TPG sur Intervest.AttachmentsEN_Intervest results squeezeout_finNL_Intervest results squeezeout_finFR_Intervest results...

Continue reading

Aedifica NV/SA: Interim financial report – Q1 2024

Please find below Aedifica’s interim financial report for the 1st quarter of the 2024 financial year. Robust operational performance driving strong results ahead of budgetEPRA Earnings* amounted to €59.8 million (+8% compared to 31 March 2023), or €1.26/share Rental income increased to €82.0 million (+8% compared to 31 March 2023) 3.3% increase in rental income on a like-for-like basis in the 1st quarter of the yearReal estate portfolio* of nearly €6 billion as at 31 March 2024623 healthcare properties for more than 47,300 end users across 8 countries Investment programme of €343 million in pre-let development projects and acquisitions in progress, of which €193 million remains to be invested. Over the 1st quarter, 10 projects from the committed pipeline were delivered for a total investment budget of approx. €74 millionSolid balance...

Continue reading

LACROIX announces the final sale of the Road Signs segment.

LACROIX announces the final saleof the Road Signs segment LACROIX announces that it has finalized the sale of its Road Signs segment to the industrial investment company AIAC (American Industrial Acquisition Corporation). The two companies had entered into exclusive negotiations on December 14, 2023. The sale, which has been approved by the relevant authorities, will take effect on April 30, 2024, at which time the segment will be removed from the Group’s scope of consolidation. This divestment reflects LACROIX’s intention to focus on group’s businesses that present strong technological synergies, to achieve its ambition of becoming a global leader in industrial IoT solutions and electronic equipment for critical applications by 2025. As part of the project, disclosed on February 8, 2023, LACROIX was committed to finding...

Continue reading

IBA signs contract with Yale New Haven Health and Hartford HealthCare to install Proteus®ONE proton therapy solution in Connecticut, US

Louvain-La-Neuve, Belgium, 2 May 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy Center, a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International, for the installation of a Proteus®ONE1 compact proton therapy system. The contract includes a multi-year operation and maintenance agreement, and it is expected that the center will start treating patients in the spring of 2026. The first downpayment has been received. The Connecticut Proton Therapy Center will be the first of its kind in the state, and located in Wallingford, Connecticut. Proton therapy treatments will be provided by physicians affiliated with the Yale School of Medicine, the Yale New Haven Smilow...

Continue reading

ING posts 1Q2024 net result of €1,578 million, with strong commercial performance

  ING posts 1Q2024 net result of €1,578 million,with strong commercial performance  1Q2024 profit before tax of €2,293 million; 4-quarter rolling return on equity of 14.8% on higher CET1 ratio of 14.8%• Net interest income from lending and liabilities remains strong• Double-digit growth in fee income, with strong contributions from both Retail and Wholesale Banking• Increase of 99,000 primary customers, net core deposits growth of €13.5 billion and net core lending growth of €4.2 billion while keeping our focus on capital efficiency• €2.5 billion share buyback as we continue to align our capital to our target level   CEO statement“We had a very strong start to 2024 with good financial and commercial results as we executed on our strategy,” said ING CEO Steven van Rijswijk. “Our total income has...

Continue reading

Regenx Granted Management Cease Trade Order by the ASC

EDMONTON, Alberta, May 01, 2024 (GLOBE NEWSWIRE) — Regenx Tech Corp., (the “Company” or “Regenx”) (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS WKN:A2DSW3) announces that, further to its April 12, 2024 and April 26, 2024 news releases, a management cease trade order (the “MCTO”) has been granted by its principal regulator, the Alberta Securities ‎Commission. As previously announced on April 12, 2024, the Corporation applied for the MCTO due to an expected delay in the filing of the audited annual financial statements, management’s discussion and analysis, and related certifications for the year ended December 31, 2023. ‎The MCTO restricts the Chief Executive Officer and Chief Financial Officer from all ‎trading in securities of the Corporation until such time as the required documents have ‎been filed by the Corporation...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.